Abstract
A simple and sensitive reversed-phase LC-ESI-MS method to identify and quantitate 5-n-butyl-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichloridephenyl)-3H-1,2,4-triazol-3-one (1b), a new Angiotensin II type 1 receptor antagonist in rat plasma has been developed and validated. Sample preparation used a simple liquid–liquid extraction with ethyl acetate. Separation was achieved by gradient elution on a C18 column. The mobile phase consisted of acetonitrile and water (0.05% triethylamine and 0.05% acetic acid) at a flow rate of 0.2 mL min−1. The detection utilized selected ion monitoring (SIM) in the negative mode at m/z 507.1 and m/z 407.2 for the deprotonated molecular ions of 1b and the internal standard irbesartan, respectively. The lower limit of quantification was reproducible at 5 ng mL−1 with 100 μL of plasma and the good linear was observed in the 5–500 ng mL−1 range. This concentration range corresponded well with the plasma concentrations of 1b in pharmacokinetic studies. Recoveries of 1b in rat plasma were 76.1, 74.6 and 79.0% at 5, 50 and 500 ng mL−1. The RSD of intra-assay and inter-assay variations were all less than 5%. This validated LC-ESI-MS assay is an economic, quick, precise and reliable method for the analysis of 1b in pharmacokinetic studies.
Similar content being viewed by others
References
Klaus O, Stumpe MD (2004) Clin Ther 26(Suppl A):33–37
Han ZJ, Yang WL (2005) Chin Pres Drugs 6:33–36
Bernard Waeber MD (2001) Curr Herap Sear 62:505–523
David HG, Smith MD (2002) Clin Ther 24:1485–1501
Xu JY, Zhou YX, Wu XM (1999) J Chin Pharm Univ 30:323–327
Wu JH, Wang QJ (2005) J Chin Pharm Univ 36:563–566
Zhang J, Wang QJ, Xu JY, Wu XM (2006) J Chin Pharm Univ 37:157–160
Burnier M, Brunner HR (2000) Lancet 355:637–645
Yeung PK, Jamieson A, Smith GJ, Fice D, Pollak PT (2000) Int J Pharm 204:17–22
Carlucci G, Palumbo G, mazzeo P, Quaglia MG (2000) J Pharm Biomed Anal 23:185–189
Soldener A, Spahn-Langguth H, Mutshler E (1998) J Pharm Biomed Anal 16:863–873
Farthing D, Sica D, Fakhry I, Pedro A, Gehr TWB (1997) J Chromatogr B 704:374–378
Gong WH, Li G, Si LQ, Huang JG (2005) Chin Pharm 8:988–990
He B, Liu SK, Peng XD, Zou JJ, Chen QH, Li ZJ, Wang XF, Xiao DW (2005) J Chin Pharm Univer 37:157–160
Gonzalez L, Lopez JA, Alonso RM, Jimenez RM (2002) J Chromatogr A 94:949–960
Cagigal E, Gonzalez L, Alonso RM, Jimenez RM (2001) Talanta 54:1121–1133
Iwasa T, Takano T, Hara K, Kamei T (1999) J Chromatogr B 734:325–330
Polinko M, Riffel K, Song H, Lo MW (2003) J Pharm Biomed Anal 33:73–84
Li P, Wang Y, Wang Y, Tang Y, Fawcett JP, Cui Y, Gu J (2005) J Chromatogr B 828:126–129
Zhang H, Fang YZ (2004) Chin J Pharm Anal 24:497–499
Tan WM, Liu C, Huang D, Ding L, Xiao H, Zhang ZX (2005) Prog Pharm Sci 29:78–82
Yang FP, Ding JS, Zhang ZH, Peng WX, Guo X (2002) Central South Pharm 2:283–285
Bonfiglio R, King RC, Olah TV, Merkle K (1999) Rapid Commun Mass Spectrom 13:1175–1185
Acknowledgments
The project was supported by the National Natural Science Foundation of People’s Republic of China (No. 30572228, 30630076) and Jiangsu Natural Science Foundation (BK2005098).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yan, B., Wang, Gj., Sun, Jg. et al. Determination of 5-n-Butyl-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichloridephenyl)-3H-1,2,4-triazol-3-one, a New Angiotensin Type 1 Receptor Antagonist in Rat Plasma by LC-ESI-MS: Application to Pharmacokinetic Studies. Chroma 66, 55–61 (2007). https://doi.org/10.1365/s10337-007-0240-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1365/s10337-007-0240-8